Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

[Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study].

Andrade-Ortega L, Irazoque-Palazuelos F, López-Villanueva R, Barragán-Navarro Y, Bourget-Pietrasanta F, Díaz-Ceballos Mde L, Hernández-Paz R, Urenda-Quezada A, Rivas-Ruiz R.

Reumatol Clin. 2010 Sep-Oct;6(5):250-5. doi: 10.1016/j.reuma.2009.11.004. Spanish.

2.

Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.

Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT, Park YB, Choe JY, Kim TJ, Park YW, Yoo DH, Bae SC, Lee HS.

Autoimmune Dis. 2012;2012:565039. doi: 10.1155/2012/565039.

3.

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation..

Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.

4.

Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.

Ale'ed A, Alsonbul A, Al-Mayouf SM.

Rheumatol Int. 2014 Apr;34(4):529-33. doi: 10.1007/s00296-013-2896-8.

PMID:
24218286
5.

Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage.

López-Longo FJ, Carol N, Almoguera MI, Olazarán J, Alonso-Farto JC, Ortega A, Monteagudo I, González CM, Carreño L.

Lupus. 2003;12(11):813-9.

PMID:
14667096
6.

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.

Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.

Nephrol Dial Transplant. 2011 Dec;26(12):3987-92. doi: 10.1093/ndt/gfr109.

7.

Rituximab therapy for childhood-onset systemic lupus erythematosus.

Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group..

J Pediatr. 2006 May;148(5):623-627. Erratum in: J Pediatr. 2006 Oct;149(4):586.

PMID:
16737873
8.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.

Arthritis Rheum. 2002 Aug;46(8):2121-31.

9.

Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.

Meinão IM, Sato EI, Andrade LE, Ferraz MB, Atra E.

Lupus. 1996 Jun;5(3):237-41.

PMID:
8803897
10.

Treating severe systemic lupus erythematosus with rituximab. An open study.

Abud-Mendoza C, Moreno-Valdés R, Cuevas-Orta E, Borjas A, Aranda F, Irazoque F, Andrade L, Vigna-Pérez M, González-Amaro R.

Reumatol Clin. 2009 Jul-Aug;5(4):147-52. doi: 10.1016/j.reuma.2008.09.008.

12.

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.

Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF.

Ann Rheum Dis. 2008 Mar;67(3):330-4. Erratum in: Ann Rheum Dis.2009 May;68(5):764.

PMID:
17827182
13.

[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.

Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Serbian.

PMID:
12583309
14.

An open study of B lymphocyte depletion in systemic lupus erythematosus.

Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.

Arthritis Rheum. 2002 Oct;46(10):2673-7.

15.
16.

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

Ezeonyeji AN, Isenberg DA.

Rheumatology (Oxford). 2012 Mar;51(3):476-81. doi: 10.1093/rheumatology/ker337.

17.

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

Arthritis Rheum. 2007 Apr;56(4):1263-72.

18.
19.

A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.

Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A.

Int Urol Nephrol. 2009;41(1):153-61. doi: 10.1007/s11255-007-9325-4.

PMID:
18214709
20.

Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus.

Dammacco F, Della Casa Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E.

Int J Clin Lab Res. 2000;30(2):67-73.

PMID:
11043499
Items per page

Supplemental Content

Support Center